CE Activity Instructions

Methotrexate and Fluorouracil Toxicities: A Collaborative Practice Approach to Prevention and Treatment


Get Permission

CE is available on May 1, 2014 and expires on May 1, 2015.

A continuing education activity for physicians, physician assistants, nurse practitioners, nurses, pharmacists, and other allied health professionals specializing in the field of oncology.

This activity is supported by an unrestricted educational grant from BTG International, Inc.

Meniscus Educational Institute
18 Elizabeth Street, Suite 300
West Conshohocken, PA 19428-2935
Phone: 610-834-1810
Fax: 610-834-8856
E-mail: email@meniscus.com
www.meniscus.com

The ASCO Post
Published by Harborside Press, LLC
37 Main Street
Cold Spring Harbor, NY 11724
Phone: 631-692-0800
Fax: 631-692-0805
E-mail: cara@harborsidepress.com
www.harborsidepress.com

© 2014, Meniscus Educational Institute. All rights reserved.

 

Faculty

Christopher J. Campen, PharmD, BCPS, BCOP, University of Arizona Cancer Center
Lee S. Schwartzberg, MD, FACP, The West Clinic
Wendy H. Vogel, MSN, FNP, AOCNP®, Wellmont Cancer Institute

Activity Rationale and Purpose

It has been clearly demonstrated that a high-quality and efficient cancer care system requires effective multidisciplinary teams that collaborate to provide patient-centered care. There is a genuine need to provide these practitioners with the skills and training to enable them to confidently carry out their responsibilities successfully.

This activity’s roundtable discussion contained a series of case studies. The participants discussed the cases from the perspective of each of their roles in collaborative practice. The roundtable discussion was used as a basis for the supplement herein. The supplement discussion focuses on the prevention and management of methotrexate- and fluorouracil-­related toxicities, especially with regard to proper dosing, monitoring, and prompt intervention. In addition, the material covers expanded access programs, including their purpose, benefits, and potential concerns.

Intended Audience

The program’s target audience consists of physicians, physician assistants, nurse practitioners, nurses, pharmacists, and other allied health professionals specializing in the field of oncology.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the effects of methotrexate- and fluorouracil-induced toxicities on managing cancer
  • Describe the appropriate strategies for managing methotrexate- and fluorouracil-induced toxicities with the advent of new agents and approaches
  • Provide strategies to promote collaborative practice initiatives for managing methotrexate- and fluorouracil-induced toxicities
  • Understand the use of expanded access program

Continuing Education

Statement of Credit—Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment, complete and submit the evaluation form with an e-mail
address) will be able to download a statement of credit via e-mail.

Physicians. The Meniscus Educational Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Meniscus Educational Institute designates this enduring material activity (271.004-1405-MJ)   for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses. This activity (271.004-1405-NJ) for 1.25 contact hours is provided by the Meniscus Educational Institute. The Meniscus Educational Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Accreditation refers to recognition of educational activities only and does not imply approval or endorsement by the Meniscus Educational Institute or the American Nurses Credentialing Center’s Commission on Accreditation of any product mentioned.

Provider approved by the California Board of Registered Nursing, Provider No. 13164, for 1.25 contact hours.

ANCC Accreditation Feedback Line: 1-866-262-9730

The Accreditation Program of the American Nurses Credentialing Center is interested in the opinions and perspectives of the participants in accredited continuing education activities, particularly perspectives related to the presence of perceived bias in an activity

Pharmacists. The knowledge-based accredited supplement is intended for pharmacists involved in the care of cancer patients. This educational activity is sponsored by the Meniscus Educational Institute. The Meniscus Educational Institute is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. The ACPE Universal Activity Number assigned to this program, for 1.25 contact hours, is 0429-9999-14-005-P.

Important Notice Concerning Pharmacy Credits:  As of January 1, 2013, a central electronic repository for CPE information will be implemented nationally to enable state boards of pharmacy to efficiently verify CE completion. During registration for any ACPE-accredited program, you will be required to provide a valid NABP e-profile ID (e-PID) number, along with your date of birth (as “MM/DD”), in order to receive credit. No CPE credit will be issued or honored by paper certificate for programs attended after January 1st; however, you may receive, at the discretion of your CPE provider, a courtesy receipt of credit for informational purposes only. Licensed pharmacists and pharmacy technicians can obtain an e-PID number by registering with the CPE Monitor through the NABP website at www.nabp.net.

 

Financial Disclosures

All individuals in positions to control the content of this program (e.g., planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Meniscus Educational Institute has identified and resolved all conflicts of interst in accordance with the Meniscus Educational Institute policies and procedures. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.

Faculty

Christopher J. Campen, PharmD, BCPS, BCOP, has nothing to disclose.
Lee S. Schwartzberg, MD, FACP, has nothing to disclose.
Wendy H. Vogel, MSN, FNP, AOCNP®, has nothing to disclose.

Education Committe and Planners

Jeannine Coronna has nothing to disclose.
Joseph Cupola has nothing to disclose.
Terry Logan, CCMEP, has nothing to disclose.
Molly Thompson has nothing to disclose.
Susan Reckling has nothing to disclose.
Christopher J. Campen, PharmD, BCPS, BCOP, has nothing to disclose.
Lee S. Schwartzberg, MD, FACP, has nothing to disclose.
Wendy H. Vogel, MSN, FNP, AOCNP®, has nothing to disclose.

Content Reviewer

Cara Glynn has nothing to disclose.
Glenn Bingle, MD, has nothing to disclose.
Karen Abbas, MS, RN, AOCN, has nothing to disclose.
William A. Bonnell, RPh, has nothing to disclose.

Pilot Study Reviewers

Glenn Bingle, MD, has nothing to disclose.
Karen Abbas, MS, RN, AOCN, has nothing to disclose.
William A. Bonnell, RPh, has nothing to disclose.

Disclaimer

This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Meniscus Educational Institute educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.

The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Meniscus Educational Institute of any specific therapeutics or approaches to diagnosis or patient management.

Product Disclosure

This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.

There is no fee for participating in this activity.

 

Meniscus Educational Institute
18 Elizabeth Street
West Conshohocken, PA 19428
Voice Mail:610-834-1810
Internet: info@meniscusedu.com

The Meniscus Educational Institute has a full complement of CE offerings on our Web site, www.meniscus.com.

How to Earn Credit

To access the learning assessment and evaluation form online, visit www.meniscusce.com

Statement of Credit—Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment and complete and submit the evaluation form with an e-mail address) will be able to download a statement of credit.


Advertisement

Advertisement



Advertisement